Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Gilbert

Showing results (141-150 of 215) with videos related to

Pageof 22
Sort By:
AIDS (London, England)|December 8, 2022
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South AfricaWilliam C McMahon, Gaurav Kwatra, Alane Izu, et al.
Nature Communications|August 8, 2022
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variantsNeeltje van Doremalen, Jonathan E Schulz, Danielle R Adney, et al.
Frontiers in Immunology|November 22, 2021
Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed PigsEleni Vatzia, Elizabeth R Allen, Tanuja Manjegowda, et al.
Infection and Immunity|April 20, 2006
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther, Fiona M Thompson, Susanna Dunachie, et al.
Scientific Reports|February 6, 2016
Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley FeverGeorge M Warimwe, Joseph Gesharisha, B Veronica Carr, et al.
Ebiomedicine|February 8, 2025
A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's diseaseJeremy Sanderson, Jeremy Aboagye, Rebecca Makinson, et al.
Biorxiv : the Preprint Server for Biology|August 19, 2022
Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamstersJulia R Port, Claude Kwe Yinda, Jade C Riopelle, et al.
Nature Communications|October 18, 2023
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamstersJulia R Port, Claude Kwe Yinda, Jade C Riopelle, et al.
The Journal of Infectious Diseases|April 11, 2013
Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infectionAlexander D Douglas, Nick J Edwards, Christopher J A Duncan, et al.
The Lancet. Infectious Diseases|April 15, 2023
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trialDaniel Jenkin, Daniel Wright, Pedro M Folegatti, et al.
Pageof 22

Showing results (141-150 of 215) with videos related to

Sort By:
Pageof 22
AIDS (London, England)|December 8, 2022
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South AfricaWilliam C McMahon, Gaurav Kwatra, Alane Izu, et al.
Nature Communications|August 8, 2022
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variantsNeeltje van Doremalen, Jonathan E Schulz, Danielle R Adney, et al.
Frontiers in Immunology|November 22, 2021
Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed PigsEleni Vatzia, Elizabeth R Allen, Tanuja Manjegowda, et al.
Infection and Immunity|April 20, 2006
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite proteinMichael Walther, Fiona M Thompson, Susanna Dunachie, et al.
Scientific Reports|February 6, 2016
Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley FeverGeorge M Warimwe, Joseph Gesharisha, B Veronica Carr, et al.
Ebiomedicine|February 8, 2025
A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's diseaseJeremy Sanderson, Jeremy Aboagye, Rebecca Makinson, et al.
Biorxiv : the Preprint Server for Biology|August 19, 2022
Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamstersJulia R Port, Claude Kwe Yinda, Jade C Riopelle, et al.
Nature Communications|October 18, 2023
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamstersJulia R Port, Claude Kwe Yinda, Jade C Riopelle, et al.
The Journal of Infectious Diseases|April 11, 2013
Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infectionAlexander D Douglas, Nick J Edwards, Christopher J A Duncan, et al.
The Lancet. Infectious Diseases|April 15, 2023
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trialDaniel Jenkin, Daniel Wright, Pedro M Folegatti, et al.
Pageof 22